There were no safety concerns identified among older adults following revaccination with the investigational respiratory syncytial virus vaccine mRNA-1345, and immune responses elicited by ...
The respiratory syncytial virus (RSV) vaccines were about 80% effective in older adults during the 2023-24 respiratory disease season, which was the first season after the shot was approved in the US, ...